Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.5%. By the end of trading, Teva Pharmaceutical Industries rose 89 cents (2.2%) to $41.44 on heavy volume. Throughout the day, five million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.1 million shares. The stock ranged in a price between $40.37-$41.61 after having opened the day at $40.37 as compared to the previous trading day's close of $40.55. Other companies within the Drugs industry that increased today were: Biostar Pharmaceuticals ( BSPM), up 20.4%, Medgenics ( MDGN), up 12.5%, Galena Biopharma ( GALE), up 9.8%, and Atossa Genetics ( ATOS), up 7.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $35.02 billion and is part of the health care sector. The company has a P/E ratio of 10.9, below the S&P 500 P/E ratio of 17.7. Shares are down 0% year to date as of the close of trading on Monday. Currently there are 16 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and eight rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share.

On the negative front, Geron Corporation ( GERN), down 23%, Neuralstem ( CUR), down 19.5%, CEL-SCI Corporation ( CVM), down 18%, and Peregrine Pharmaceuticals ( PPHM), down 12.2%, were all laggards within the drugs industry with Onyx Pharmaceuticals ( ONXX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon